M. Shen

Molecular Biology · Genes & Development · 2009–2018

A researcher in the Science corpus: 3 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom M. Shen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. F. d’Adda di Fagagna
  2. Jane E. Visvader
  3. L. Salmena
  4. S. Morrison
  5. R. Pardal
  6. Hans Lilja

Who trusts M. Shen overall

  1. Guocan Wang

Papers from M. Shen's perspective

Ordered by how strongly the researchers M. Shen trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Molecular determinants of resistance to antiandrogen therapy (Nature Medicine)
  2. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. (Proceedings of the National Academy of Sciences of the United States of America)
  3. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer (Nature)
  4. Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases (Cancer Research)
  5. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate (Nature Genetics)
  6. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. (Cancer Research)
  7. Role of the TMPRSS2-ERG gene fusion in prostate cancer. (Neoplasia)
  8. The polycomb group protein EZH2 is involved in progression of prostate cancer (Nature)
  9. Gene expression correlates of clinical prostate cancer behavior. (Cancer Cell)
  10. Splicing of a novel AR exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance (Cancer Research)

Their papers